These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson's disease treatment. Lee MH; Kang S; Um KH; Lee SW; Hwang H; Baek K; Choi JW J Transl Med; 2024 Jan; 22(1):53. PubMed ID: 38218903 [TBL] [Abstract][Full Text] [Related]
5. AAV-based in vivo gene therapy for neurological disorders. Ling Q; Herstine JA; Bradbury A; Gray SJ Nat Rev Drug Discov; 2023 Oct; 22(10):789-806. PubMed ID: 37658167 [TBL] [Abstract][Full Text] [Related]
6. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. Huang L; Wan J; Wu Y; Tian Y; Yao Y; Yao S; Ji X; Wang S; Su Z; Xu H Life Sci; 2021 Apr; 270():119142. PubMed ID: 33524419 [TBL] [Abstract][Full Text] [Related]
7. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease. Janelidze S; Nordström U; Kügler S; Brundin P J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717 [TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications. Ye D; Chukwu C; Yang Y; Hu Z; Chen H Adv Drug Deliv Rev; 2024 Aug; 211():115363. PubMed ID: 38906479 [TBL] [Abstract][Full Text] [Related]
14. AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice. Liguore WA; Domire JS; Button D; Wang Y; Dufour BD; Srinivasan S; McBride JL Mol Ther; 2019 Nov; 27(11):2018-2037. PubMed ID: 31420242 [TBL] [Abstract][Full Text] [Related]
15. AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges. Kang L; Jin S; Wang J; Lv Z; Xin C; Tan C; Zhao M; Wang L; Liu J J Control Release; 2023 Mar; 355():458-473. PubMed ID: 36736907 [TBL] [Abstract][Full Text] [Related]
16. Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Vassalli G; Büeler H; Dudler J; von Segesser LK; Kappenberger L Int J Cardiol; 2003 Aug; 90(2-3):229-38. PubMed ID: 12957756 [TBL] [Abstract][Full Text] [Related]
17. A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting. Chtarto A; Bockstael O; Tshibangu T; Dewitte O; Levivier M; Tenenbaum L Br J Clin Pharmacol; 2013 Aug; 76(2):217-32. PubMed ID: 23331189 [TBL] [Abstract][Full Text] [Related]
18. Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids. Chamberlain K; Riyad JM; Weber T Hum Gene Ther Methods; 2016 Feb; 27(1):1-12. PubMed ID: 26757051 [TBL] [Abstract][Full Text] [Related]
19. Enhancing transduction of the liver by adeno-associated viral vectors. Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909 [TBL] [Abstract][Full Text] [Related]
20. A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna. Taghian T; Marosfoi MG; Puri AS; Cataltepe OI; King RM; Diffie EB; Maguire AS; Martin DR; Fernau D; Batista AR; Kuchel T; Christou C; Perumal R; Chandra S; Gamlin PD; Bertrand SG; Flotte TR; McKenna-Yasek D; Tai PWL; Aronin N; Gounis MJ; Sena-Esteves M; Gray-Edwards HL Mol Ther; 2020 Feb; 28(2):411-421. PubMed ID: 31813800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]